Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

BI 113608 Administered as Tablets Twice Daily Over 4 Weeks in Patients With Chronic Obstructive Pulmonary Disease Associated With Chronic Bronchitis

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo to BI 113608 medium dose b.i.d.
Drug: Placebo to BI 113608 high dose b.i.d.
Drug: Placebo to BI 113608 low dose b.i.d.
Drug: BI 113608 medium dose b.i.d.
Drug: BI 113608 high dose b.i.d.
Drug: BI 113608 low dose b.i.d.

First Posted Date: 2013-10-08

Last Posted Date: 2017-01-20

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 84

Registration Number: NCT01958008

Locations: 🇩🇪
Boehringer Ingelheim Investigational Site, Mannheim, Germany

Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran

Phase 1

Completed

Conditions: Hemorrhage

Interventions: Drug: BI 655075
Drug: Placebo

First Posted Date: 2013-10-07

Last Posted Date: 2016-02-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 46

Registration Number: NCT01955720

Locations: 🇧🇪
1321.2.1 Boehringer Ingelheim Investigational Site, Antwerpen, Belgium

Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis

Phase 3

Terminated

Conditions: Arthritis, Rheumatoid

Interventions: Drug: BI 695500

First Posted Date: 2013-10-07

Last Posted Date: 2018-01-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 91

Registration Number: NCT01955733

Locations: 🇺🇸
1301.4.5809 Boehringer Ingelheim Investigational Site, Pembroke Pines, Florida, United States
🇺🇸
1301.4.5585 Boehringer Ingelheim Investigational Site, Birmingham, Alabama, United States
🇺🇸
1301.4.5765 Boehringer Ingelheim Investigational Site, El Cajon, California, United States

and more 40 locations

Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

Phase 3

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Afatinib

First Posted Date: 2013-10-01

Last Posted Date: 2019-08-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 542

Registration Number: NCT01953913

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳
Shanghai Chest Hospital, Shanghai, China
🇨🇳
Shanghai Pulmonary Hospital, Shanghai, China

and more 30 locations

To Determine the Maximum Tolerated Dose (MTD) of BIBF 1120 in Patients With Solid Tumours

Phase 1

Completed

Conditions: Malignant Solid Tumour

Interventions: Drug: BIBF 1120

First Posted Date: 2013-09-27

Last Posted Date: 2013-09-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 61

Registration Number: NCT01951846

Locations: 🇩🇪
Klinik für Tumorbiologie, Abteilung Internistische Onkologie, Freiburg, Germany

Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma

Phase 1

Completed

Conditions: Lymphoma, Follicular

Interventions: Drug: BI 695500
Drug: MabThera

First Posted Date: 2013-09-25

Last Posted Date: 2018-09-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 95

Registration Number: NCT01950273

Locations: 🇧🇪
UZ Leuven, Leuven, Belgium
🇩🇪
Haemato-Onkologie Hamburg, Hamburg, Germany
🇩🇪
Klinikum Kassel GmbH, Kassel, Germany

and more 26 locations

Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Empagliflozin

First Posted Date: 2013-09-23

Last Posted Date: 2014-12-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT01947855

Locations: 🇯🇵
1245.35.002 Boehringer Ingelheim Investigational Site, Shinjyuku-ku, Tokyo, Japan
🇯🇵
1245.35.001 Boehringer Ingelheim Investigational Site, Suita-shi, Osaka, Japan

Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®.

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Metformin
Drug: Linagliptin

First Posted Date: 2013-09-20

Last Posted Date: 2015-02-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT01947153

Locations: 🇷🇺
1288.21.1 Boehringer Ingelheim Investigational Site, St. Petersburg, Russian Federation

Ipratropium Bromide in Peri-Operative COPD

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: ipratropium bromide
Drug: placebo

First Posted Date: 2013-09-17

Last Posted Date: 2016-10-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 192

Registration Number: NCT01943552

Locations: 🇨🇳
244.2514.86002 Boehringer Ingelheim Investigational Site, Tianjin, China
🇨🇳
244.2514.86006 Boehringer Ingelheim Investigational Site, Guangzhou, China
🇨🇳
244.2514.86009 Boehringer Ingelheim Investigational Site, Hangzhou, China

and more 6 locations

Iota-Carrageenan Nasal Spray in Common Cold

Phase 4

Completed

Conditions: Common Cold

Interventions: Device: Placebo
Device: Iota-Carrageenan

First Posted Date: 2013-09-17

Last Posted Date: 2015-04-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 200

Registration Number: NCT01944631

Locations: 🇬🇧
1326.1.44001 Boehringer Ingelheim Investigational Site, Cardiff, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy